NEW YORK(GenomeWeb) – Epigenetic service provider Zymo announced on Monday it has become an Illumina Certified Service Provider for next-generation sequencing. 

Zymo said it underwent a two-step process including minimum data generation, data certification, and an on-site audit of the facility and process to ensure that it follows Illumina CsPro best practices for customer communication, sample and reagent management, library preparation and sequencing, and data processing. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.